Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Veradigm stock price, quote, forecast and news

MDRX
US01988P1084
607917

Price

9.32
Today +/-
+0.11
Today %
+1.30 %
P

Veradigm stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Veradigm stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Veradigm stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Veradigm stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Veradigm's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Veradigm Stock Price History

DateVeradigm Price
8/7/20249.32 undefined
8/6/20249.20 undefined
8/5/20249.37 undefined
8/2/20249.65 undefined
8/1/20249.75 undefined
7/31/20249.65 undefined
7/30/20249.66 undefined
7/29/20249.65 undefined
7/26/20249.70 undefined
7/25/20249.65 undefined
7/24/20249.65 undefined
7/23/20249.80 undefined
7/22/20249.65 undefined
7/19/20249.90 undefined
7/18/20249.73 undefined
7/17/20249.81 undefined
7/16/20249.85 undefined
7/15/20249.85 undefined
7/12/20249.85 undefined
7/11/20249.85 undefined

Veradigm Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Veradigm, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Veradigm from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Veradigm’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Veradigm. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Veradigm’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Veradigm’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Veradigm’s growth potential.

Veradigm Revenue, EBIT and net profit per share

DateVeradigm RevenueVeradigm EBITVeradigm Net Income
2028e864.76 M undefined181.66 M undefined157 M undefined
2027e788.26 M undefined141.78 M undefined118.58 M undefined
2026e822.17 M undefined241.03 M undefined59.57 M undefined
2025e781.52 M undefined222.05 M undefined128.03 M undefined
2024e654.15 M undefined85.74 M undefined73.56 M undefined
2023e634.73 M undefined98.31 M undefined94.42 M undefined
2022e626.35 M undefined133.31 M undefined89.3 M undefined
20211.5 B undefined89 M undefined134.4 M undefined
20201.5 B undefined-56 M undefined700.4 M undefined
20191.63 B undefined-63.1 M undefined-182.2 M undefined
20181.62 B undefined-96.7 M undefined363.7 M undefined
20171.5 B undefined12.5 M undefined-196.5 M undefined
20161.39 B undefined72.4 M undefined-25.7 M undefined
20151.39 B undefined33.4 M undefined-2.2 M undefined
20141.38 B undefined-36.8 M undefined-66.5 M undefined
20131.37 B undefined-100.1 M undefined-104 M undefined
20121.45 B undefined24.4 M undefined-1.2 M undefined
20111.44 B undefined136.5 M undefined73.6 M undefined
2010704.5 M undefined104.6 M undefined61.6 M undefined
2009548.4 M undefined45.9 M undefined25.6 M undefined
2008383.8 M undefined40.2 M undefined25.4 M undefined
2007281.9 M undefined28.1 M undefined20.6 M undefined
2006228 M undefined19.9 M undefined11.9 M undefined
2005120.6 M undefined9.2 M undefined9.7 M undefined
2004100.8 M undefined3.2 M undefined3.1 M undefined
200385.8 M undefined-6.3 M undefined-5 M undefined
200278.8 M undefined-17.1 M undefined-15.2 M undefined

Veradigm Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022e2023e2024e2025e2026e2027e2028e
0.030.030.030.030.030.020.030.060.070.080.090.10.120.230.280.380.550.71.441.451.371.381.391.391.51.621.631.51.50.630.630.650.780.820.790.86
--3.13--9.09-23.3317.39103.7027.2711.438.9717.6520.0090.0023.2536.3043.0828.47105.110.14-5.050.290.65-8.018.020.93-7.970.07-58.351.283.1519.425.25-4.149.64
34.3834.3827.2730.3030.0026.0918.5221.828.5724.3635.2942.0045.0050.4449.8253.7953.2855.1146.0541.9138.8939.6541.8543.3642.2238.4037.3837.6241.18-------
1111910965126193042541151402062923886656065345465806016326216105656190000000
00-5-3-7-7-16-54-106-17-6391928404510413624-100-36337212-96-63-56891339885222241141181
---15.15-9.09-23.33-30.43-59.26-98.18-151.43-21.79-7.063.007.508.339.9610.448.2114.779.421.66-7.28-2.612.385.190.80-5.94-3.86-3.735.9221.2515.4613.0028.4329.3217.8920.95
-3-3-5-3-11-9-13-57-418-15-539112025256173-1-104-66-2-25-196363-18270013489947312859118157
--66.67-40.00266.67-18.1844.44338.46633.33-96.41-66.67-160.00200.0022.2281.8225.00-144.0019.67-101.3710,300.00-36.54-96.971,150.00684.00-285.20-150.14-484.62-80.86-33.585.62-22.3475.34-53.91100.0033.05
0.40.41.72.936.114.727.937.838.338.641.643.153.464.782.9127148.4191178.7177179.8185.1186.2180.8176166.3159.3138.70000000
------------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Veradigm Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Veradigm is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (B)CURRENT ASSETS (B)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (B)OTHER NON-CURRENT ASSETS (B)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (k)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (B)LONG-T. LIAB. (B)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
19961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021
0.20.755.697.240.536.416.839.8115.35749.50.371.2143.4129.4157.81046353.2116.996.6119.5174.2129.7531.1132.5
9.69.55.113.914.518.718.221.429.255.681.448.3155.1181.9317.2362.8302.1313.5331.6327.9405.2492.6531.7555.7454.1235.1
000.41.20.70.70.30.60.500000000000000025.40
2.62.93.65.36.243.22.42.23.24.21.92.63.23.800000000000
000000000.010.040.030.010.030.080.130.140.170.160.10.090.10.250.150.160.141.19
0.010.010.070.120.060.060.040.070.150.150.170.060.260.410.580.660.570.540.490.540.60.860.860.841.151.55
1.51.84.911.88.44.42.22.42.814.118.26.117.324.6114.3122.6155.5174145.8125.6148.8135.4121.9186.4168.828.1
00022.737.828.934.588.530.82613.583.71.91.71.71.71.31.30149.10011.310.712.3
000000000000000000000071.967.643.728.2
4.63.7-8.5-34.86.716.117.115.690.3131.68.6241.3236.5616588.2522.6544.2489.5433.4905.3630.4640.7618.1479.8224.4
000.010.15000.010.010.010.190.240.080.420.411.041.041.041.191.21.221.921.291.371.360.970.51
000000000.010.010.010.010.010.010.070.090.060.170.140.360.11.310.110.120.090.07
0.010.010.010.190.050.040.070.130.070.320.410.120.690.691.841.851.782.081.982.143.233.372.322.361.760.87
0.020.020.070.310.120.10.110.190.220.480.580.180.951.092.422.52.352.622.462.683.834.233.183.212.922.43
19.441.30.20.30.40.40.40.40.40.50.60.81.41.52.52.52.62.62.72.72.72.72.72.72.72.8
0.020.020.130.410.640.640.640.650.660.850.850.280.850.891.471.541.581.721.751.791.791.781.881.911.91.96
-43.3-50.8-62-119.4-538.3-553.5-558.5-555.4-545.7-533.8-513.2-173.3-147.3-84.4-90-16.4-17.5-121.6-188-190.2-187.4-338.2132.8-49.3633.1767.6
0-0.2-1.6-1-0.10.30.1-0.6-1-0.1-0.10002.3-0.60-1.9-2-4.2-55.80.70.20-1.8-2.8
000000000000000010010000-6,000-2,700-5,600-4,40000
-0.010.010.070.290.10.090.080.090.110.320.340.110.70.811.381.531.561.61.561.61.541.442.011.862.542.73
6.77.84.475.24.56.168.69.315.914.319.232.346.641.245.97370.860126.185.773.210435.95.3
1.91.31.75.39.47.37.912.213.826.531.722.358.174.7125.1121.4105.4145.7106.1108133.1146.7179.8326.9203.591.7
000.61.93.96.51114.617.335.545.927.286104228.6288.9287.5282317332.4381.1628.4523.7415.3695.4501
2.540000000003.200000000000000
4.7000000000.30.61.10.81.130.845.579.316.427.512.626.728.821.1364.500
0.020.010.010.010.020.020.030.030.040.070.090.070.160.210.430.50.520.520.520.510.670.890.81.210.930.6
0.010000000.080.080.090.1400.0600.460.320.360.550.540.611.30.910.650.550.170.35
0000000003.96.2020.471.388.5119.7125.979.721.122.2141.823.358.52118.216.6
0000.20.30.22.10.20.30.42.10.54.14.555.587.558.5159.798.4115.357.8816.696.6137.8130.852.4
0.010000000.080.080.090.1400.090.080.60.530.550.780.660.751.51.750.80.710.320.42
0.030.010.010.010.020.020.030.120.120.160.240.070.250.291.031.031.071.31.181.262.172.641.61.921.251.02
0.020.020.070.310.120.10.110.210.230.480.580.180.951.092.422.562.632.92.742.863.714.083.613.783.793.75
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Veradigm provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Veradigm's financial health and stability.

Assets

Veradigm's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Veradigm must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Veradigm after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Veradigm's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (B)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
19951996199719981999200020012002200320042005200620072007200820092010201020112012201320142015201620172018201920202021
-2-2-10-7-11-57-418-15-539112520252662-573-1-104-66-23-154407-182-132134
111122868545616162116223650132150178174161136157192207192176
000000-4800006292-131-333-12-430-2-4-104-38-3-2
-2-200-1-8-1-2430-13-40-24-40-35-79-6374-49161857-60-18-152-23
0072-212367100154442930267688838473127233-44111723-324
000000000033030227131113151515212819245
00000000000001091011-1777556104376330
-3-3-1-4-12-25-33-10512162773073613975268222811032112432476746-106-75
00-10-4-9-3-4-3-5-5-14-1-21-1-19-35-61-105-123-116-67-67-124-157-144-130-105-78
00-00-0.01-0.05-0.01-0.01-0.01-0.080.02-0.18-0.01-0.09-0.01-0.26-0.030.11-0.1-0.12-0.25-0.11-0.29-1.15-0.410.25-0.161.62-0.01
0000-0.01-0.04-0.01-0-0.01-0.080.02-0.17-0.01-0.07-0.01-0.2400.170.010-0.14-0.04-0.22-1.03-0.260.39-0.031.720.07
00000000000000000000000000000
442-3-4-20007900-150-1-21-45466-1247210444594185-283271-764175
000969110020-79134090-461-669-16-220621103-121-10-137-111-334-417
3325641080107291340600296-35-203-143-154131-4142865198-29367-1,109-258
00000000000010136580-2-6-35-10-689223128-93-10-16
00000000000000000000000000000
00003936-42-16-4343-18-11-17072-1428-53-41-963-453422-47399-347
-3.6-3.6-2.9-5.1-17.1-34.4-36.7-15.22.16.811.412.66.68.86.617.1104.914.3163.799.6-35.236.4144119.690.9-76.7-84.1-211.7-154
00000000000000000000000000000

Veradigm stock margins

The Veradigm margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Veradigm. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Veradigm.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Veradigm's sales revenue. A higher gross margin percentage indicates that the Veradigm retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Veradigm's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Veradigm's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Veradigm's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Veradigm. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Veradigm's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Veradigm Margin History

Veradigm Gross marginVeradigm Profit marginVeradigm EBIT marginVeradigm Profit margin
2028e41.22 %21.01 %18.16 %
2027e41.22 %17.99 %15.04 %
2026e41.22 %29.32 %7.25 %
2025e41.22 %28.41 %16.38 %
2024e41.22 %13.11 %11.25 %
2023e41.22 %15.49 %14.88 %
2022e41.22 %21.28 %14.26 %
202141.22 %5.92 %8.94 %
202037.65 %-3.73 %46.61 %
201937.38 %-3.87 %-11.16 %
201838.41 %-5.98 %22.48 %
201742.25 %0.83 %-13.12 %
201643.38 %5.22 %-1.85 %
201541.88 %2.41 %-0.16 %
201439.63 %-2.67 %-4.83 %
201338.93 %-7.29 %-7.57 %
201241.93 %1.69 %-0.08 %
201146.09 %9.45 %5.1 %
201055.19 %14.85 %8.74 %
200953.28 %8.37 %4.67 %
200853.91 %10.47 %6.62 %
200749.8 %9.97 %7.31 %
200650.83 %8.73 %5.22 %
200545.52 %7.63 %8.04 %
200442.26 %3.17 %3.08 %
200335.78 %-7.34 %-5.83 %
200225.25 %-21.7 %-19.29 %

Veradigm Stock Sales Revenue, EBIT, Earnings per Share

The Veradigm earnings per share therefore indicates how much revenue Veradigm has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Veradigm earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Veradigm's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Veradigm’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Veradigm's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Veradigm Revenue, EBIT and net profit per share

DateVeradigm Sales per ShareVeradigm EBIT per shareVeradigm Earnings per Share
2028e8.03 undefined0 undefined1.46 undefined
2027e7.32 undefined0 undefined1.1 undefined
2026e7.64 undefined0 undefined0.55 undefined
2025e7.26 undefined0 undefined1.19 undefined
2024e6.08 undefined0 undefined0.68 undefined
2023e5.9 undefined0 undefined0.88 undefined
2022e5.82 undefined0 undefined0.83 undefined
202110.84 undefined0.64 undefined0.97 undefined
20209.43 undefined-0.35 undefined4.4 undefined
20199.82 undefined-0.38 undefined-1.1 undefined
20189.19 undefined-0.55 undefined2.07 undefined
20178.28 undefined0.07 undefined-1.09 undefined
20167.44 undefined0.39 undefined-0.14 undefined
20157.49 undefined0.18 undefined-0.01 undefined
20147.66 undefined-0.2 undefined-0.37 undefined
20137.76 undefined-0.57 undefined-0.59 undefined
20128.09 undefined0.14 undefined-0.01 undefined
20117.56 undefined0.71 undefined0.39 undefined
20104.75 undefined0.7 undefined0.42 undefined
20094.32 undefined0.36 undefined0.2 undefined
20084.63 undefined0.48 undefined0.31 undefined
20074.36 undefined0.43 undefined0.32 undefined
20064.27 undefined0.37 undefined0.22 undefined
20052.8 undefined0.21 undefined0.23 undefined
20042.42 undefined0.08 undefined0.07 undefined
20032.22 undefined-0.16 undefined-0.13 undefined
20022.06 undefined-0.45 undefined-0.4 undefined

Veradigm business model

Allscripts Healthcare Solutions Inc is one of the leading companies in the digital healthcare sector in the USA. The company was founded in 1982 and has since become one of the most important providers of IT solutions in healthcare. Allscripts supports healthcare providers in improving patient care and efficiency through the development and provision of innovative software and IT solutions. The business model of Allscripts is based on the development and sale of web-based software solutions for medical documentation and hospital management. These solutions are mainly distributed to hospitals and practices through subscriptions or licenses. Allscripts offers a variety of products that focus on various areas of medical care. One of the main divisions of the company is the electronic health records system (EHR). This system allows for the electronic recording, storage, and management of medical data and information. This enables healthcare providers to quickly and easily access patient information and document important diagnoses and treatments. Another important division of Allscripts is the Revenue Cycle Management (RCM), which optimizes billing and payment processes in hospitals and practices. In addition, Allscripts also offers solutions for telemedicine, including patient portal applications, remote patient monitoring systems, and mobile apps for patients and providers. Allscripts is based in Chicago and employs over 10,000 employees in various countries. The company also maintains partnerships with other companies in healthcare to facilitate and improve the complexity of digital transformation in the healthcare market. This includes companies like Microsoft, who work together with Allscripts on the development of artificial intelligence for healthcare applications. Allscripts' portfolio of offerings is very broad and provides customers with a variety of software solutions for different areas of medical care. The products are particularly characterized by their user-friendly interfaces, flexibility, and scalability. This allows customers to customize the solutions to their specific needs and consider future requirements. However, some products have been criticized for their expandability, poor design, and slow loading times. Recently, Allscripts has made a number of investments in research and development to address these issues and optimize the applications. In summary, Allscripts Healthcare Solutions Inc is considered one of the leading providers of software and IT solutions in healthcare in the USA. Thanks to a wide range of products and close collaboration with partners in healthcare, Allscripts is able to offer its customers innovative and scalable solutions that help them optimize their business processes and improve the quality of their medical care. Veradigm is one of the most popular companies on Eulerpool.com.

Veradigm SWOT Analysis

Strengths

1. Strong Reputation: Allscripts Healthcare Solutions Inc has established itself as a reputable and trusted provider of healthcare solutions in the industry.

2. Comprehensive Product Portfolio: The company offers a wide range of healthcare software products and services, including electronic health records (EHRs) and practice management systems.

3. Established Customer Base: Allscripts has a large and diverse customer base, including healthcare organizations of varying sizes and specialties.

Weaknesses

1. Intense Competition: Allscripts faces significant competition from other healthcare software companies, which may impact its market share and pricing power.

2. Reliance on Third-Party Systems: The company's software solutions often integrate with third-party systems, which can introduce risks related to interoperability and compatibility.

3. Limited Global Presence: Allscripts' market presence outside of the United States is relatively small compared to some of its competitors.

Opportunities

1. Growing Healthcare IT Market: The increasing digitization of healthcare and the demand for efficient solutions present opportunities for Allscripts to expand its customer base.

2. Expansion into Telehealth: The COVID-19 pandemic has accelerated the adoption of telehealth. Allscripts can explore opportunities to enhance its telehealth capabilities and tap into this growing market.

3. Strategic Partnerships: Collaborating with healthcare providers, technology companies, and other stakeholders can enable Allscripts to develop innovative solutions and expand its market reach.

Threats

1. Regulatory Changes: Frequent changes in healthcare regulations can create challenges for Allscripts in terms of compliance and adapting its software to new requirements.

2. Data Security Risks: The increasing volume and sensitivity of healthcare data pose significant risks in terms of data breaches and cybersecurity threats.

3. Economic Uncertainty: Economic downturns or budget constraints within the healthcare industry can impact the purchasing decisions of potential customers, affecting Allscripts' revenue.

Veradigm Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Veradigm historical P/E ratio, EBIT, and P/S ratio.

Veradigm shares outstanding

The number of shares was Veradigm in 2023 — This indicates how many shares 138.7 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Veradigm earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Veradigm's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Veradigm’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Veradigm's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Veradigm.

Veradigm latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/20220.19 0.23  (21.44 %)2022 Q3
6/30/20220.15 0.18  (16.5 %)2022 Q2
3/31/20220.22 0.13  (-39.79 %)2022 Q1
12/31/20210.33 0.79  (140.34 %)2021 Q4
9/30/20210.19 0.27  (44.39 %)2021 Q3
6/30/20210.18 0.23  (29.36 %)2021 Q2
3/31/20210.16 0.19  (21.1 %)2021 Q1
12/31/20200.22 0.29  (33.95 %)2020 Q4
9/30/20200.19 0.2  (3.57 %)2020 Q3
6/30/20200.12 0.18  (46.34 %)2020 Q2
1
2
3
4
5
...
9

Eulerpool ESG Scorecard© for the Veradigm stock

Eulerpool World ESG Rating (EESG©)

48/ 100

🌱 Environment

13

👫 Social

65

🏛️ Governance

67

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
❌
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Veradigm list of shareholders

%
Name
Stocks
Change
Date
9.75 % Newtyn Management, LLC10,500,0009,038,3082/28/2024
8.34 % Dimensional Fund Advisors, L.P.8,977,589-103,33412/31/2023
5.57 % Kent Lake Capital LLC6,000,0004,500,0003/1/2024
5.39 % Wellington Management Company, LLP5,806,2973,140,48312/31/2023
3.99 % State Street Global Advisors (US)4,290,596216,34512/31/2023
3.43 % The Vanguard Group, Inc.3,697,374-10,556,9192/29/2024
3.16 % D. E. Shaw & Co., L.P.3,398,754-235,48412/31/2023
3.13 % William Blair Investment Management, LLC3,368,359-1,006,64612/31/2023
2.34 % Pacer Advisors, Inc.2,516,5741,307,02412/31/2023
2.28 % Fuller & Thaler Asset Management Inc.2,454,590-88,65212/31/2023
1
2
3
4
5
...
10

Veradigm Executives and Management Board

Ms. Tejal Vakharia49
Veradigm Senior Vice President, General Counsel - Marketing and Government Affairs
Compensation 2.08 M
Mr. P. Gregory Garrison69
Veradigm Executive Chairman of the Board (since 2015)
Compensation 303,000
Mr. Jonathan Judge68
Veradigm Independent Director
Compensation 301,000
Mr. Dave Stevens60
Veradigm Independent Director
Compensation 281,500
Ms. Carol Zierhoffer62
Veradigm Lead Independent Director
Compensation 277,500
1
2
3

Veradigm Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
3M Co Stock
3M Co
SupplierCustomer0,850,180,13-0,61-0,630,04
Streamline Health Sol Stock
Streamline Health Sol
SupplierCustomer0,750,960,750,48-0,470,15
BIO-key Stock
BIO-key
SupplierCustomer0,750,880,630,22-0,59-0,71
Pure Storage A Stock
Pure Storage A
SupplierCustomer0,700,940,850,340,380,71
Citrix Systems Stock
Citrix Systems
SupplierCustomer0,310,720,770,540,04-0,64
RELX Stock
RELX
SupplierCustomer0,270,860,260,110,300,68
UnitedHealth Group Stock
UnitedHealth Group
SupplierCustomer0,170,790,680,640,730,83
Wolters Kluwer Stock
Wolters Kluwer
SupplierCustomer0,090,560,38-0,24-0,070,61
WISeKey International Holding B Stock
WISeKey International Holding B
SupplierCustomer0,010,890,75-0,40-0,72-0,47
Microsoft Stock
Microsoft
SupplierCustomer-0,180,150,59-0,47-0,020,67
1
2

Most common questions regarding Veradigm

What values and corporate philosophy does Veradigm represent?

Allscripts Healthcare Solutions Inc represents the values of innovation, collaboration, and patient-centered care. With a commitment to improving healthcare technology, Allscripts aims to transform the way healthcare is delivered and experienced. The company values a collaborative approach, working closely with healthcare providers and patients to develop solutions that enhance clinical outcomes and patient satisfaction. Allscripts prioritizes the use of advanced technology and data analytics to drive better healthcare decision-making and deliver personalized care. Through its comprehensive suite of software and services, Allscripts aims to empower healthcare organizations to deliver efficient, high-quality care to their patients.

In which countries and regions is Veradigm primarily present?

Allscripts Healthcare Solutions Inc is primarily present in the United States of America.

What significant milestones has the company Veradigm achieved?

Allscripts Healthcare Solutions Inc has achieved several significant milestones in its history. The company has successfully launched innovative products, expanded its market share, and entered into strategic partnerships within the healthcare industry. Allscripts Healthcare Solutions Inc has also received industry recognition for its excellent performance and dedication to providing high-quality healthcare solutions. By continuously investing in research and development, the company has consistently improved its technology offerings, contributing to the overall advancement of healthcare services. With its commitment to excellence, Allscripts Healthcare Solutions Inc continues to shape the future of healthcare with its groundbreaking solutions and services.

What is the history and background of the company Veradigm?

Allscripts Healthcare Solutions Inc is a leading healthcare information technology company established in 1986. The company features a rich history and background, having grown from a small startup to a global provider of electronic health records (EHR), practice management systems, and population health management solutions. Allscripts is dedicated to enhancing patient care by empowering healthcare organizations with innovative technology. With a strong presence in the healthcare industry, Allscripts serves over 180,000 physicians and more than 2,500 hospitals worldwide. Continuously evolving and expanding its offerings, Allscripts Healthcare Solutions Inc remains at the forefront of the digital healthcare revolution.

Who are the main competitors of Veradigm in the market?

The main competitors of Allscripts Healthcare Solutions Inc in the market include Cerner Corporation, Epic Systems Corporation, and Meditech.

In which industries is Veradigm primarily active?

Allscripts Healthcare Solutions Inc is primarily active in the healthcare industry.

What is the business model of Veradigm?

Allscripts Healthcare Solutions Inc is a leading healthcare technology company that provides innovative solutions and services to healthcare organizations. The business model of Allscripts revolves around the development and provision of electronic health record (EHR) systems, practice management software, and other healthcare IT solutions. By offering integrated platforms, Allscripts enables healthcare providers to streamline operations, improve patient care, and enhance clinical outcomes. With a focus on promoting interoperability and connectivity, Allscripts facilitates efficient data exchange across healthcare settings. By leveraging technology and data analytics, Allscripts aims to optimize workflows, enhance decision-making processes, and ultimately improve the overall delivery of healthcare services.

What is the P/E ratio of Veradigm 2024?

The Veradigm P/E ratio is 17.57.

What is the P/S ratio of Veradigm 2024?

The Veradigm P/S ratio is 1.98.

What is the AlleAktien quality score of Veradigm?

The AlleAktien quality score for Veradigm is 1/10.

What is the revenue of Veradigm 2024?

The expected Veradigm revenue is 654.15 M USD.

How high is the profit of Veradigm 2024?

The expected Veradigm profit is 73.56 M USD.

What is the business model of Veradigm

Allscripts Healthcare Solutions Inc is an American company specializing in providing IT solutions for healthcare providers. The company was founded in 1986 as a small software firm in Chicago and has since become one of the leading providers of electronic health records and other health IT solutions. Allscripts offers a wide range of products and services to meet the needs of healthcare providers of all sizes and types. The various business areas of Allscripts include hospitals and health systems, physician practices, accountable care organizations (ACOs), and pharmacies. Allscripts' products and services are designed to increase the efficiency of healthcare providers, improve the quality of patient care, and meet the growing demand for connected healthcare. In the hospital and health systems area, Allscripts offers a comprehensive portfolio of solutions to meet the complex requirements of large and complex health systems. This includes electronic health records, laboratory and imaging management, portfolio management, revenue cycle management, and reporting. In the physician practices area, Allscripts provides a variety of solutions to increase the efficiency of individual practices and smaller group practices. Products in this area include electronic health records, appointment scheduling, billing, prescription management, and patient portals. For ACOs, Allscripts offers a variety of solutions to support the community of healthcare facilities and providers. This includes solutions for collaboration management, population health management, and the automation of clinical workflows. Allscripts' solutions are also of interest to pharmacies. Allscripts offers solutions for optimizing inventory management, billing, and patient care. The company relies on state-of-the-art IT solutions and implements industry-leading methods for data analysis. Allscripts employs over 8,600 employees and has customers in over 190 countries. The company demonstrates its commitment to innovation in the healthcare industry through the development of new products and services. For example, a program to enhance the functionality of implanted pacemakers was recently introduced, which can be operated directly from a smartphone via a secure cloud system. With the introduction of new products and solutions, Allscripts aims to further expand its business in the healthcare sector and strengthen its position as a leading provider of health IT solutions. In summary, Allscripts Healthcare Solutions Inc is a leading provider of health IT solutions that offers a wide range of products and services for healthcare providers of all sizes and types. Allscripts aims to make healthcare more sustainable, digital, and connected, and to increase the efficiency of the healthcare system through innovative solutions.

What is the Veradigm dividend?

Veradigm pays a dividend of 0 USD distributed over payouts per year.

How often does Veradigm pay dividends?

The dividend cannot currently be calculated for Veradigm or the company does not pay out a dividend.

What is the Veradigm ISIN?

The ISIN of Veradigm is US01988P1084.

What is the Veradigm WKN?

The WKN of Veradigm is 607917.

What is the Veradigm ticker?

The ticker of Veradigm is MDRX.

How much dividend does Veradigm pay?

Over the past 12 months, Veradigm paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Veradigm is expected to pay a dividend of 0 USD.

What is the dividend yield of Veradigm?

The current dividend yield of Veradigm is .

When does Veradigm pay dividends?

Veradigm pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Veradigm?

Veradigm paid dividends every year for the past 0 years.

What is the dividend of Veradigm?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Veradigm located?

Veradigm is assigned to the 'Health' sector.

Wann musste ich die Aktien von Veradigm kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Veradigm from 8/9/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/9/2024.

When did Veradigm pay the last dividend?

The last dividend was paid out on 8/9/2024.

What was the dividend of Veradigm in the year 2023?

In the year 2023, Veradigm distributed 0 USD as dividends.

In which currency does Veradigm pay out the dividend?

The dividends of Veradigm are distributed in USD.

All fundamentals about Veradigm

Our stock analysis for Veradigm Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Veradigm Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.